Treatment of chronic hypercalcemia

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Hypercalcemia is a common clinical finding, frequently associated with primary hyperparathyroidism (PHPT) and malignancy-associated hypercalcemia (MAH).
• Initial management involves rehydration and loop diuretics, with bisphosphonates as the mainstay for long-term treatment.
• Calcitonin offers short-term control for severe hypercalcemia.

Purpose of the Study:

• To review current and emerging therapeutic strategies for managing hypercalcemia.
• To compare the efficacy of different agents in treating PHPT and MAH.
• To highlight novel treatments targeting bone resorption pathways.

Main Methods:

• Review of existing literature on hypercalcemia treatments.
• Comparison of bisphosphonates (zoledronate, clodronate, pamidronate) for MAH.
• Evaluation of calcimimetic agents for PHPT.
• Discussion of emerging therapies targeting parathyroid hormone-related peptide (PTHrP) and receptor activator of nuclear factor-κ ligand (RANKL).

Main Results:

• Bisphosphonates are effective, with zoledronate showing superiority in MAH treatment.
• Calcimimetics provide an alternative for PHPT when surgery is not feasible.
• Novel agents like anti-PTHrP antibodies and denosumab (anti-RANKL antibody) demonstrate potential for superior bone resorption suppression.

Conclusions:

• Bisphosphonates remain a cornerstone for hypercalcemia management.
• Emerging therapies, including calcimimetics and monoclonal antibodies targeting RANKL, offer new avenues for treatment, particularly in refractory cases.
• Further research into novel agents like denosumab is warranted for their potential to surpass bisphosphonate efficacy.